Skip to main content

Month: June 2020

Indberetning af insideres handel med FirstFarms A/S’ aktier

I henhold til Markedsmisbrugsforordningen art. 19, og i henhold til fuldmagt til at indberette handler for Wefri A/S, skal FirstFarms A/S hermed indberette oplysninger om ledende medarbejderes og disses nærtståendes transaktioner med FirstFarms A/S’ aktier og tilknyttede værdipapirer:Med venlig hilsenFirstFarms A/SFor yderligere information:Se venligst vores hjemmeside www.firstfarms.dk eller kontakt adm. direktør Anders H. Nørgaard på telefon +45 75 86 87 87.Om FirstFarms:FirstFarms er et dansk børsnoteret selskab, der opkøber og driver landbrug i Østeuropa. Vi udvikler de enkelte landbrug til moderne virksomheder, der leverer mælk, kød og korn af bedste kvalitet til de lokale fødevarevirksomheder. FirstFarms bidrager til, og bifalder, udviklingen mod et mere bæredygtigt landbrug.Vedhæftet fil(12) Insideres handel – Wefri

Continue reading

Green Growth Brands Announces Court Approval of Sale and Investment Solicitation Process and Extension of Stay under Insolvency Proceedings

COLUMBUS, Ohio, June 02, 2020 (GLOBE NEWSWIRE) — Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) and certain of its direct and indirect wholly owned subsidiaries (collectively “GGB“, the “Company” or the “Applicants”) today provided an update on its insolvency proceedings under the Companies’ Creditors Arrangement Act (Canada) (“CCAA“).As announced on May 20, 2020, the Company filed for insolvency protection under the CCAA and obtained an order from the Ontario Superior Court of Justice (the “Court”) granting the Applicants protection under the CCAA for an initial 10 day period until May 29, 2020, as extended until June 12, 2020.On June 2, 2020, the Court granted a motion filed by the Company and issued an order (the “Amended and Restated Order”): (i) extending the stay period until August 15,...

Continue reading

2020-06-02 Nombre d’actions & nombre de droits de vote au 31-05-2020

TIVOLY Société Anonyme au capital de 11 079 900 eurosSiège Social : 266 route Portes de Tarentaise – 73790 Tours-en-SavoieR.C.S. Chambéry : 076 120 021•Ce nombre est calculé sur la base de l’ensemble des actions auxquelles sont attachés desdroits de vote, y compris les actions privées de droits de vote, conformément à l’article 223-11du Règlement général de l’Autorité des Marchés Financiers relatif au calcul desfranchissements des seuils de nombre de droits de vote.**A titre d’information, nombre calculé « net »des actions privées de droits de vote.Le 02 Juin 2020 www.tivoly.com TIVOLY est un groupe industriel qui a pour vocation la conception, la production et lacommercialisation d’outils de coupe et de produits et services associés destinés aux professionnels de lafabrication et de la maintenance, aux artisans et aux particul...

Continue reading

Valneva Announces Publication in The Lancet of Complete Phase 1 Data for its Single-Shot Chikungunya Vaccine Candidate

Saint-Herblain (France), June 2, 2020 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, announced today the publication of full data from the Phase 1 clinical trial of its chikungunya vaccine candidate, VLA1553, in the peer-reviewed medical journal The Lancet Infectious Diseases.The Lancet paper provides a detailed analysis of final Phase 1 results and supports the continued clinical development of VLA1553.Wolfgang Bender, Ph.D., M.D., Chief Medical Officer of Valneva, commented, “We reported excellent Phase 1 results1 for our single-shot chikungunya vaccine and we’re pleased that these important results are now fully available to the broader infectious disease community. Millions of people have been affected by chikungunya and our objective is to help address this ongoing public health crisis as soon as we can.”Valneva...

Continue reading

Valneva annonce la publication dans le Lancet de l’intégralité des résultats de Phase 1 pour son candidat vaccin à injection unique contre le chikungunya

Saint-Herblain (France), 2 juin 2020 – Valneva SE (“Valneva” ou “le Groupe”), société spécialisée dans les vaccins a annoncé aujourd’hui la publication de l’intégralité des résultats cliniques de Phase 1 pour son vaccin à injection unique contre le chikungunya, VLA1553, dans la revue médicale « Lancet Infectious Diseases ».L’article du Lancet fournit une analyse détaillée des résultats finaux de Phase 1 et plaide en faveur de la poursuite du développement clinique de VLA1553.Wolfgang Bender, Ph.D., M.D., Directeur Médical de Valneva, a indiqué, “Nous avons publié d’excellent résultats de Phase1 pour notre vaccin à injection unique contre le chikungunya et nous nous réjouissons que l’intégralité de ces résultats soient désormais accessibles par toute la communauté médicale des maladies infectieuses. Des millions de personnes ont...

Continue reading

COFACE SA : Déclaration du nombre total des droits de vote et du nombre d’actions composant le capital social au 31 mai 2020

Paris, le 2 juin 2020 – 17h45                                                    COFACE SA : Déclaration du nombre total des droits de vote et du nombre d’actions composant le capital social au 31 mai 2020y compris actions auto-détenuesdéduction faite des actions auto-détenuesPièce jointe2020 05 31 Declaration Actions&Droits de Vote FR

Continue reading

Number of voting rights as of May 31, 2020

Nicox SASociété anonyme with a registered capital of € 33,491,370Head Office:DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642On June 2, 2020,MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS(Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF)—————www.nicox.comPhone: +33 4-97-24-53-00Fax : +33  4-97-24-53-99Attachment31 mai 2020 EN

Continue reading

Nombre de droits de vote au 31 mai 2020

Nicox SASociété anonyme au capital de 33 491 370 eurosSiège social :DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642Le 2 juin 2020,PUBLICATION MENSUELLE DU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE(Article L.233-8 II du Code de Commerce et les Articles 221-1 et 223-16 du Règlement général de l’AMF)—————www.nicox.comTel :   04-97-24-53-00Fax :  04-97-24-53-99Pièce jointe31 mai 2020 FF

Continue reading

Inventiva to participate at the Jefferies Virtual Healthcare Conference

Daix (France), June 2, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that Frédéric Cren, Chairman, CEO and cofounder of Inventiva, will participate in a fireside chat and engage in one-on-one investor meetings at the upcoming Jefferies Virtual Healthcare Conference, being held virtually on June 2-4, 2020.The event details of the fireside chat are as follows:Date: Thursday, June 4, 2020Time: 8:00 am – 8:25 am (Eastern Time)Format: Video presentationLive and replay link: http://wsw.com/webcast/jeff126/iva/The presentation document and the above link will also be available on Inventiva’s website in the “Investors”...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.